EDISON values SYGNIS at 37.5 million euros
EDISON published a thorough analysis of SYGNIS Pharma AG . As a result of EDISON’s analysis of the company, the objective value of SYGNIS, taking into account the launch of QualiPhi in the third quarter of 2013 – licensed by Qiagen – as well as the license of two further products this year: PrimPol and Double Switch, would reach 37.5 million euros.
In order to undertake the analysis of the share value of SYGNIS, EDISON focused on the predicted income of three products: QualiPhi, PrimPol and Double Switch. Meanwhile, EDISON have not considered any additional products the company has been developing (DNA repair kit).
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.